Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Magnetic resonance angiography

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    81 result(s) found for: Magnetic resonance angiography. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2007-003263-52 Sponsor Protocol Number: BONN_Vaso07 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Bonn
    Full Title: Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in d...
    Medical condition: Comparision between two diagnostic methods (DSA and MRA) to evaluate supraaortale arteries using three different contrast mediums
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007683 Carotid angiography LLT
    9.1 10057784 MRI angiography LLT
    9.1 10065324 Digital subtraction angiography LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000690-78 Sponsor Protocol Number: 19773 Start Date*: 2018-10-29
    Sponsor Name:Bayer AG
    Full Title: LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem
    Medical condition: Contrast enhancement in magnetic resonance imaging (MRI) for central nervous system (CNS), magnetic resonance (MR) angiography, liver, kidney and other body regions
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10028049 MRI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003141-42 Sponsor Protocol Number: EX9924-4473 Start Date*: 2019-07-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Ongoing) CZ (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004207-11 Sponsor Protocol Number: Gd-NEPHRIC-01 Start Date*: 2006-01-03
    Sponsor Name:Malmö University Hospital, Dep of Radiology
    Full Title: Single blind study comparing nephrotoxicity in patients with decreased renal function after intravenous gadodiamide(Omniscan) or gadopenteate (Magnevist) injection in routine clinical Magnetic Reso...
    Medical condition: Patients with diabetes (type I or II) and impaired renal function defined as pre-study serum creatinine ≥150µmol/l if man and 133µmol/l if woman or an estimated prestudy glomerular filtration rate ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002940-28 Sponsor Protocol Number: ISRCTN46528154 Start Date*: 2006-10-09
    Sponsor Name:ICIN [...]
    1. ICIN
    2. UMCG, Van Buchem Stichting
    Full Title: HEBE III: A prospective, randomised, double blind, placebo controlled clinical study to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute m...
    Medical condition: Patients with a successful primary PCI (TIMI 2/3) for a first acute myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000994-69 Sponsor Protocol Number: SOV302 Start Date*: 2004-11-11
    Sponsor Name:Amersham Buchler GmbH & Co KG an affiliate of GE Healthcare Bio-Sciences
    Full Title: A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries
    Medical condition: Suspected or proven chronic PAOD predominantly located in the aorto-iliac region of Fontaine Stages IIb to IV (ie, Rutherford Stages I3-III), or presents with an ankle brachial pressure index of <0...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10062585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006014-41 Sponsor Protocol Number: Vasovist MA-01 Start Date*: 2008-04-14
    Sponsor Name:University Heidelberg, University Hospital Mannheim
    Full Title: Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Arte...
    Medical condition: Patients suffering from PAOD stage III or stage IV (confirmed by ECCM MRA, CTA, non-selective DSA, DUS) and have an indication for the evaluation of the entire lower leg axis down to the feet (comm...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002939 Aortoiliac occlusive disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000449-15 Sponsor Protocol Number: DIONYSIUS Start Date*: 2020-12-11
    Sponsor Name:Amsterdam University Medical Centers, location AMC
    Full Title: Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
    Medical condition: Ischemic diabetic foot ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002547-66 Sponsor Protocol Number: 308861 Start Date*: 2005-11-28
    Sponsor Name:Schering AG
    Full Title: Intra-individual open-label multicenter comparison study of magnetic resonance angiography (MRA) with the blood pool contrast agent Vasovist® and a conventional extracellular contrast agent with in...
    Medical condition: Patients who have aortoiliac disease Fontaine-stage IIb – IV and an indication for the evaluation of the infrarenal aorta and the peripheral run-off arteries (i.e. from infrarenal aorta to calves).
    Disease: Version SOC Term Classification Code Term Level
    7.1 10002939 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002730-11 Sponsor Protocol Number: A091031 Start Date*: 2007-11-30
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Magnetic resonance (MR) angiography with a blood pool contrast medium.
    Medical condition: Abnormalities of the major venous system.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047184 Vein disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004700-20 Sponsor Protocol Number: 2104-02 Start Date*: 2005-03-11
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE)
    Medical condition: Detection of venous thromboembolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021526-36 Sponsor Protocol Number: LMU_Rad_MR_GadoMRA01 Start Date*: 2011-04-07
    Sponsor Name:Klinikum der Universität München
    Full Title: Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine ...
    Medical condition: Supraaortic vessel disease; suspicion or proven carotid artery stenosis / stenoses
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004521-32 Sponsor Protocol Number: D5780C00007 Start Date*: 2018-08-22
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006277-24 Sponsor Protocol Number: EFC6145 Start Date*: 2008-04-10
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LI...
    Medical condition: Critical Limb Ischemia with skin lesions
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) CZ (Completed) GR (Completed) ES (Completed) AT (Completed) FI (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006719-20 Sponsor Protocol Number: 0431-082 Start Date*: 2009-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
    Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000929-59 Sponsor Protocol Number: MultiH/BRA/708 Start Date*: Information not available in EudraCT
    Sponsor Name:Bracco ALTANA Pharma GmbH
    Full Title: INTRAINDIVIDUAL CROSS-OVER STUDY TO COMPARE MULTIHANCE® AND MAGNEVIST® AT A DOSE OF 0.1 MMOL/KGBW IN CERVICO-CEREBRAL MR ANGIOGRAPHY AND CEREBRAL MR PERFUSION IMAGING AT 3 TESLA IN PATIENTS WITH CA...
    Medical condition: Carotid artery stenosis and scheduled for MRA, for MR perfusion examination and for an elective stent treatment
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007687 Carotid artery stenosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005715-32 Sponsor Protocol Number: SOCODIHF Start Date*: 2017-12-07
    Sponsor Name:Karolinska Institutet Stockholm, Sweden
    Full Title: SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF)
    Medical condition: Patients with type 2 diabetes mellitus and heart failure of ischemic origin
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006022-25 Sponsor Protocol Number: WA28119 Start Date*: 2013-05-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS
    Medical condition: Giant cell arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) AT (Completed) DE (Completed) DK (Completed) GB (Completed) PT (Completed) NL (Completed) ES (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001574-18 Sponsor Protocol Number: ESR-14-10076 Start Date*: 2016-01-20
    Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA
    Full Title: TICAGRELOR IN PATIENTS WITH STABLE ISCHEMIC HEART DESEASE WITH ELEVATION OF TROPONIN
    Medical condition: patients with stable ischemic heart disease with elevation of troponin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10055218 Ischemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003088-36 Sponsor Protocol Number: TCMR0007/06 Start Date*: 2008-02-15
    Sponsor Name:AININCAR
    Full Title: Efecto de la Infusión Intracoronaria de Células Progenitoras de Médula Ósea sobre la Regeneración Miocárdica en Pacientes con Miocardiopatía Dilatada. Estudio Cínico-Biológico. Effects of intracoro...
    Medical condition: Miocardiopatía dilatada de origen idiopático Idiopathic Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059868 Non-ischemic dilated cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 01:23:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA